The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Abstract
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2-3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.Methods This randomised, open-label, phase 2-3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab-bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03794440. The study is closed to new participants and follow-up is ongoing for long-term outcomes.Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab-bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8-46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5-11·7) in the sintilimab-bevacizumab biosimilar group and 10·0 months (8·4-11·7) in the sorafenib group. Patients in the sintilimab-bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1-5·7]) than did patients in the sorafenib group (2·8 months [2·7-3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46-0·70; p<0·0001). In the first interim analysis of overall survival, sintilimab-bevacizumab biosimilar showed a significantly longer overall survival than did sorafenib (median not reached [95% CI not reached-not reached] vs 10·4 months [8·5-not reached]; HR 0·57, 95% CI 0·43-0·75; p<0·0001). The most common grade 3-4 treatment-emergent adverse events were hypertension (55 [14%] of 380 patients in the sintilimab-bevacizumab biosimilar group vs 11 [6%] of 185 patients in the sorafenib group) and palmar-plantar erythrodysaesthesia syndrome (none vs 22 [12%]). 123 (32%) patients in the sintilimab-bevacizumab biosimilar group and 36 (19%) patients in the sorafenib group had serious adverse events. Treatment-related adverse events that led to death occurred in six (2%) patients in the sintilimab-bevacizumab biosimilar group (one patient with abnormal liver function, one patient with both hepatic failure and gastrointestinal haemorrhage, one patient with interstitial lung disease, one patient with both hepatic faliure and hyperkalemia, one patient with upper gastrointestinal haemorrhage, and one patient with intestinal volvulus) and two (1%) patients in the sorafenib group (one patient with gastrointestinal haemorrhage and one patient with death of unknown cause).Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients.Funding Innovent Biologics.Translation For the Chinese translation of the abstract see Supplementary Materials section.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [119]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Cited by
Sorted by citations
Items 301–400 of 1,000
Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022
Zhang, L., Liu, R., Deng, T., & Ba, Y. (2023) · Cancer Innovation · doi:10.1002/cai2.60 · Cited by 15
“Similarly, the ORIENT ‐ 32 study demonstrated that first ‐ line sintili-mab (PD ‐ 1 antibody) plus bevacizumab was superior to sorafenib [27].”
Far, B. F., Rabie, D., Hemati, P., Fooladpanjeh, P., Hamedanchi, N. F., Lomer, N. B., Rouzbahani, A. K., & Naimi‐Jamal, M. R. (2023) · Livers · doi:10.3390/livers3010011 · Cited by 16
“Sintilimab was found to outperform sorafenib in the Chinese ORIENT-32 study in combination with IBI305 (bevacizumab biosimilar) [68].”
BackgroundLin, L.-W., Ke, K., Yan, L., Chen, R., & Huang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1178428 · Cited by 16
Xu, Z., Ye, Z., Tang, Y., Deng, D., Zhou, Q., Fang, M., Zhang, Y., & Li, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5724 · Cited by 18
Li, J., Kong, M., Yu, G., Wang, S., Shi, Z., Han, H., Lin, Y., Shi, J., & Song, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188308 · Cited by 16
Yang, H., Yang, T.-S., Qiu, G., & Liu, J. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s423684 · Cited by 16
“2%).(13,14) In the ORIENT-32 trials and IMBRAVE 150, ≥3 grade AE were 61.”
BackgroundOuyang, J., Yang, Y. A., Zhou, Y., Ye, F., Wang, Z., Li, Q., Xu, Y., Li, L., Zhao, X., Zhang, W., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10580-3 · Cited by 16
Self-citationLiu, Q., Li, R., Li, L., Wang, G., Ji, S., Zheng, X., Jia, X., Tao, H., & Hu, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231206274 · Cited by 16
Li, X., Wang, J., Guo, Z., Ma, Y., Xu, D., Fan, D., Dai, P., Chen, Y., Liu, Q., Jiao, J., et al. (2023) · Aging · doi:10.18632/aging.205334 · Cited by 15
“ICIs have become the keystone in the treatment for unresectable hepatocellular carcinoma [53, 85].”
BackgroundSelf-citationLiu, X., Lu, Y., Zhou, W., Peng, T., Zhou, J., Bi, H., Feng, X., & Chen, X. (2024) · Liver Cancer · doi:10.1159/000535496 · Cited by 17
Self-citationLin, Y., Wu, G., Rao, M., Liu, Y. H., Han, Y. W., Zhang, J., & Zhang, J. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-62523-z · Cited by 16
“In our study, the CR rate was 1.2% lower than in the IMbrave150 study 6 and 1.2%–3.8% higher than that in other studies 7–9 , 18 .”
BackgroundResultInfluentialGong, H., Ong, S. C., Fan, L., Shen, Y., Weng, Z., Zhao, K., Jiang, Z., & Wang, M. (2024) · Health Economics Review · doi:10.1186/s13561-024-00526-2 · Cited by 18
“…these are studies on atezolizumab plus bevacizumab [14], cabozantinib plus atezolizumab [15], sintilimab plus a bevacizumab biosimilar (IBI305) [16], tislelizumab [17], camreli-zumab plus rivoceranib [18], pembrolizumab plus len-vatinib [19, 20], nivolumab [21], and durvalumab plus…”
BackgroundZuo, M., Zheng, G., Cao, Y., Lu, H., Li, D., An, C., & Fan, W. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001940 · Cited by 16
Xiang, Z., Ma, L., Fu, Y., & Pan, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411571 · Cited by 16
Zhu, H., Zhao, W., Chen, H., Zhu, X., You, J., & Jin, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1468440 · Cited by 16
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
Zanuso, V., Rimassa, L., & Braconi, C. (2023) · Hepatology · doi:10.1097/hep.0000000000000572 · Cited by 16
“[15] Patients in the combination arm had a longer median PFS [4.6 mo (95% CI, 4.1 – 5.7) versus 2.8 mo (95% CI, 2.7 – 3.2); HR 0.56; 95% CI, 0.46 – 0.70; p < 0.0001]; and median OS [not reached (NR) (95% CI, NR – NR) vs. 10.4 mo (95% CI, 8.5 – NR); HR 0.57; 95% CI, 0.43 – 0.75; p < 0.0001] than…”
InfluentialGolgi-protein 73 facilitates vimentin polymerization in hepatocellular carcinoma
Hu, X., Yuan, S., Zhou, S., Sun, T., Wang, C., Ying, S., Zhu, H., Luo, J., Jin, H., & Liu, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85431 · Cited by 15
Chen, Q., Sun, Q., Zhang, J., Li, B., Feng, Q., & Liu, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295090 · Cited by 15
Yang, C., Xuan, T., Gong, Q., Dai, X., Wang, C., Zhang, R., Zhao, W., Wang, J., Yue, W., & Li, J. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15310 · Cited by 14
“…and an antiangiogenic agent has been an effective strategy for the treatment of primary hepatocellular carcinoma as well as many solid tumors with LM. 39,46,47 More importantly, LM from lung cancer have been shown to respond to treatment in a way to more like liver cancer than primary lung cancer.”
BackgroundSelf-citationLiu, H., Wang, C., Wang, R., Cao, H., Cao, Y., Huang, T., Lu, Z., Xiao, H., Hu, M., Wang, H., et al. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.02.06 · Cited by 17
Chen, S., Shuangyan, T., Shi, F., Cai, H., Wu, Z., Wang, L., Ma, P., Zhou, Y.-M., Mai, Q., Wang, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430571 · Cited by 17
Progress on angiogenic and antiangiogenic agents in the tumor microenvironment
Xu, J., & Tang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1491099 · Cited by 20
Self-citationWang, J., He, Y., Zhang, B., Lv, H., Nie, C., Chen, B., Xu, W., Zhao, J., Cheng, X., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924149 · Cited by 14
Self-citationLin, Y., Ruze, R., Zhang, R., Tuergan, T., Wang, M., Tulahong, A., Zhu, D., Yuan, Z., Jiang, T., Aji, T., et al. (2024) · Liver Cancer · doi:10.1159/000542578 · Cited by 17
Treatment for hepatocellular carcinoma after immunotherapy
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101781 · Cited by 16
Gao, W., Pan, Z.-L., Xiao-hui, Z., Yang, L., Cao, J., Li, D., Zheng, H.-J., Liu, C., Li, G., Bao, X., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103217 · Cited by 16
“11 Furthermore, the ZGDH3 study indicated that donafenib was superior to sorafenib in improving overall survival (OS), making it more suitable for Chinese patients.”
Self-citationFulgenzi, C. A. M., D’Alessio, A., Ogunbiyi, O., Demirtaş, C. Ö., Gennari, A., Cortellini, A., Sharma, R., & Pinato, D. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2072726 · Cited by 14
“Only patients with preserved liver function (Child-Pugh A) were included in IMbrave150 and ORIENT-32 studies, and as a consequence, the safety and efficacy of the combination in Child-Pugh B patients are unknown.”
MethodRecent therapeutics in hepatocellular carcinoma.
Fan, Z., Zhou, P., Jin, B., Li, G., Feng, L., Zhuang, C., & Wang, S. (2023) · PubMed Central · Cited by 14
Wu, S., Ruan, D., Wu, Q., Tang, Y., Zhang, J., Cai, S., Zhou, Y., Luo, J.-W., & Fang, Z.-T. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s408819 · Cited by 14
“The IMbrave150 and ORIENT-32 Phase III trials have shown that combined treatment with ICIs and anti-angiogenic drugs is effective for uHCC.(8,9) However, the Checkmate-459 (Nivolumab vs sorafenib) and Keynote-240 (Pembrolizumab vs placebo) studies revealed negative results.”
BackgroundJia, G., Qiu, L., Zheng, H., Qin, B., Sun, Z., Shao, Y., Yang, Z., Shao, J., Zhou, Y., & Jiao, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11064-1 · Cited by 14
“In addition, sintilimab and tislelizumab have also shown good efficacy and safety in clinical trials [11, 12].”
BackgroundChen, Q., Chen, S., Chen, M., Lyu, N., & Zhao, M. D. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00403 · Cited by 14
“22 In China, the combination of “sintilimab plus a bevacizumab biosimilar” 23 and “camre-lizumab with apatinib” 24 resulted in ORR of 20.5% and 34% respectively.”
BackgroundInfluentialSelf-citationWang, L., Feng, J.-K., Lu, C., Wu, J., Zhou, B., Wang, K., Wei, X., Liang, C., Zhou, H., Shi, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae032 · Cited by 14
Self-citationTreatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future
Wei, H., Dong, C., & Li, X. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00462 · Cited by 16
“72 Early studies found that the OS benefit of tislelizumab is non-inferior to that of sorafenib, with a higher objective response rate and more durable response, while the median progression-free survival of sorafenib is longer.”
BackgroundWang, J., Liu, R., Zhao, Y., Ma, Z., Sang, Z., Wen, Z., Yang, X., & Xie, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743055 · Cited by 14
“(3) The high daily dose (> 800 mg every day) of TKIs such as sorafenib could induce not only a heavy financial burden but also side effects (13).”
BackgroundSelf-citationZhong, Y. M., Huo, H., Dai, S., & Su, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964779 · Cited by 14
“(23) showed that the PFS of PD-1 combined with antiangiogenic drugs and without PD-1 were HR=4.”
BackgroundInfluentialConstruction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response
Wang, X.-X., Wu, L., Dou, Q.-Y., Ai, L., Lu, Y., Deng, S., Liu, Q., Ji, H., & Zhang, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1034928 · Cited by 14
“, 2020a), ORIENT-32 phase 3 trial (Sintilimab plus bevacizumab similar IBI305) (Ren et al., 2021), COSMIC-312 (Cabozantinib plus Atezolizumab) phase 3 trial (Kelley et al.”
BackgroundSelf-citationImmune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors
Sarantis, P., Trifylli, E.-M., Koustas, E., Papavassiliou, K. A., Karamouzis, M. V., & Papavassiliou, A. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113612 · Cited by 14
“Another combination is IBI305 (biosimilar of bevacizumab) and sintilimab, and another PD-1 inhibitor in phase II/III (NCT03794440) in comparison with sorafenib is a first-line choice for HBV-related unresectable HCC cases [32].”
BackgroundTargeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
Fu, S., Wang, Z., Li, C., Li, Y., Zhang, K., Zhong, Z., & Zhong, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094770 · Cited by 13
Li, X., Kang, J., Yue, J., Xu, D., Liao, C., Zhang, H., Zhao, J., Liu, Q., Jiao, J., Wang, L., et al. (2023) · Aging · doi:10.18632/aging.204680 · Cited by 14
Hu, Y., Pan, T., Cai, X., He, Q.-S., Zheng, Y., Huang, M., Jiang, Z., Chen, J., & Wu, C. T. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-486 · Cited by 13
“J Gastrointest Oncol 2023;14(4):1837-1848 | https://dx.”
ResultSelf-citationHsu, C., Chang, Y., Yen, C., Xu, Y., Dong, M., & Tong, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-03098-w · Cited by 13
Hu, Z.-X., Xu, X., Wang, Z., Huang, J., Li, W.-C., Zhang, S., Shen, J., Zhong, B., & Zhu, X. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s439660 · Cited by 13
Wang, Y., Weng, W., Liang, R., Zhou, Q., Hu, H., Li, M., Chen, L., Chen, S., Peng, S., Kuang, M., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s437415 · Cited by 13
Self-citationZhang, L., & Lu, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60574-1 · Cited by 13
Dawood, Z. S., Brown, Z. J., Alaimo, L., Lima, H. A., Shaikh, C. F., Katayama, E., Munir, M. M., Moazzam, Z., Endo, Y., Woldesenbet, S., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.02.003 · Cited by 13
Leung, J. H., Wang, S.-Y., Leung, H. W. C., & Chan, A. L. F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1344798 · Cited by 15
Huang, L., Kang, D., Zhao, C., & Liu, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-54945-6 · Cited by 13
Zhang, Y., Zhang, H., Xu, H., Wang, Y., Feng, L., & Yi, F. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03396-4 · Cited by 13
“%) may be better than that of patients receiving other first-line systemic treatment [13, 19, 21, 44, 45].”
BackgroundSelf-citationWerner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14
“201 In addition, the randomized phase III IMbrave050 trial demonstrated that adjuvant treatment with the atezolizumab/bevacizumab combination after resection or ablation improved recurrence-free survival versus active surveillance, 202 further highlighting the growing impact of ICI in curative…”
A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
Su, X., Li, Y., Ren, Y., Cao, M., Yang, G., Luo, J., Hu, Z., Deng, H., Deng, M., Liu, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116902 · Cited by 14
Self-citationWen, F., Huang, P., Wu, Q., Yang, Y., Zhou, K., Zhang, M., & Li, Q. (2024) · Cancer Medicine · doi:10.1002/cam4.70094 · Cited by 14
Self-citationLee, C. L., Freeman, M., Burak, K. W., Moffat, G. T., O’Donnell, C. D. J., Ding, P. Q., Lyubetska, H., Meyers, B. M., Gordon, V. L., Kosyachkova, E., et al. (2024) · Cancers · doi:10.3390/cancers16162878 · Cited by 14
“Similar results were recapitulated in the ORIENT-32 trial with the combination of sintilimab and IBI305, a bevacizumab biosimilar [14].”
MethodResultShao, Y., & Akhmetzhanov, A. R. (2024) · Liver Cancer · doi:10.1159/000542576 · Cited by 15
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Nagalapuram, V., Popuri, N., Nipp, R. D., Ulahannan, S. V., & Lau‐Min, K. S. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00872 · Cited by 14
Zhang, B., Tao, B., Li, Y., Yi, C., Lin, Z., Ma, Y., Han, J., Shao, W., Chen, Z., Lin, J., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.12.025 · Cited by 14
Self-citationZou, X., Xu, Q., You, R., & Yin, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s399874 · Cited by 13
“Besides, ORIENT-32 study also show the combination of sintilimab plus bevacizumab achieved better outcomes over sorafenib alone.(31) All above-mentioned provide the theoretical principle and excellent practical basis for the combined strategy of regorafenib and PD-1 inhibitors.”
Self-citationSystemic therapy in advanced hepatocellular carcinoma
Ahn, J. C., Tran, N. H., & Yang, J. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0051 · Cited by 14
Qi, W., Peng, W. J., Qi, X., Qiu, Z., Wen, T., & Li, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138570 · Cited by 13
“The results of two multicenter phase III studies (Imbrave150 (25) and ORIENT32 (26)) showed that overall survival (OS) and progression-free survival (PFS) in the combination therapy group were significantly better than those in the monotherapy group.”
BackgroundLin, K., Lin, Z.-W., Chen, Q.-J., Luo, L., Zhang, J., Chen, J., Wang, K., Tai, S., Zhang, Z.-B., Wang, S.-F., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10561-6 · Cited by 13
“…(3 mg/kg body weight intravenously every 2 weeks) [23], tislelizumab (200 mg intravenously every 3 weeks) [24], and sintilimab (200 mg intravenously every 3 weeks) [25], chosen based on the most recent efficacy and safety data, patient economic status, and drug availability at each medical center.”
MethodHuang, Y., Zhang, Y., Zhang, M., Zhao, K., Feng, L., Guan, J., Dong, R., Liu, J., Tian, D., Liu, M., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104070 · Cited by 13
Sidali, S., Campani, C., An, J., Shim, J. H., & Nault, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0746 · Cited by 12
Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement
Llovet, J. M., Mauro, E., Rimassa, L., Mazzaferro, V., Pinter, M., Kelley, R. K., Chan, S. L., Kulik, L., Pillai, A. A., Roberts, L. R., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01160-z · Cited by 13
“First-line ICI-based regimens available in China include: camrelizumab plus rivoceranib (CARES-310) 188 ; sintilimab plus IBI305 (ORIENT-32) 169 ; anlotinib plus penpulimab (APOLLO) 189 ; and tislelizumab (RATIONALE-301) 121 . f These treatments demonstrated non-inferiority compared with sorafenib. g For single lesion…”
InfluentialCure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
Chu, P., & Chan, S. (2021) · Cancers · doi:10.3390/cancers13215295 · Cited by 11
“More recently, a similar result was also obtained from a phase II/III trial in China testing a combination of another ICI, sintilimab, and IBI305, a bevacizumab biosimilar, versus sorafenib as a front-line treatment for patients with unresectable HBV-associated HCC [48].”
ResultShao, G., Bai, Y., Yuan, X., Chen, X., Gu, S., Gu, K., Hu, C., Liang, H., Guo, Y., Wang, J., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101679 · Cited by 12
Self-citationZhang, Z., Jiao, T., Li, J., Hu, B., Zhang, W., Wang, Z., Wan, T., Wang, Y., & Lu, S. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02939-5 · Cited by 12
“Anti-PD-1 antibodies were intravenously administered as follows: nivolumab (240 mg every 2 weeks) or pembrolizumab (200 mg every 3 weeks), or sintilimab [20] (200 mg every 3 weeks).”
Self-citationPan, Y., Zhu, X., Liu, J., Zhong, J., Zhang, W., Shen, S., Jin, R., Liu, H., Ye, F., Hu, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138355 · Cited by 12
“Systemic agents were administered according to the product package inserts and previous studies, based on current efficacy and safety data, prior treatment, and drug access (21).”
MethodSelf-citationLei, Z., Ma, W., Si, A., Zhang, Y., Yang, F., Yu, Q., Tang, H., Xiao, Q., Zhou, J., Wang, K., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17623 · Cited by 12
Self-citationWang, T., Feng, L., Zhong, S. S., Yang, L., Yu, X., Wu, J., Sun, J., Zhang, J., Feng, Y., & Wang, W. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17823 · Cited by 12
Self-citationCombination treatment of HCC with SBRT and immune checkpoint inhibition
Podesta, C., Kayani, M., Goody, R. B., & Samson, A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104191 · Cited by 13
Li, Z., Xu, Y., Qu, W., Liu, P., Zhu, Y., Li, H., Guo, Y., & Liu, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.14121 · Cited by 12
Self-citationWu, J., Wu, J., Liu, D.-Y., Li, H., Zhuang, S.-W., Li, B., Zhou, J., Huang, J., Zhang, Z., Li, S.-Q., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s442341 · Cited by 12
Self-citationWu, D., Jia, B., Jia, M., Zhao, H., Zhao, H., & Zhou, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1274754 · Cited by 12
Gao, B., Yang, F., Zheng, D., Hu, S., Liu, J., Liu, H., Liu, Y., Liu, L., Wang, R., Zhao, Y., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s443041 · Cited by 12
“Besides, the efficacy and safety of these two ICIs have been confirmed in randomized controlled trials for advanced HCC. 11,32 In addition to camrelizumab and sintilimab, other ICIs such as tislelizumab, pembrolizumab, and toripalimab have also been used in similar studies.”
BackgroundLin, Z.-P., Hu, X., Chen, D., Huang, D.-B., Zou, X.-G., Zhong, H., Xu, S.-X., Chen, Y., Li, X., & Zhang, J. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i17.2321 · Cited by 12
Self-citationZhang, X., Zheng, P., Meng, B., Zhuang, H., Lu, B., Yao, J., Han, F., & Luo, S. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01399-9 · Cited by 12
Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma
Papadakos, S. P., Chatzikalil, E., Vakadaris, G., Reppas, L., Arvanitakis, K., Koufakis, T., Siakavellas, S. I., Manolakopoulos, S., Germanidis, G. S., & Theocharis, S. E. (2024) · Cancers · doi:10.3390/cancers16142609 · Cited by 12
“Similarly, the ORIENT-32 study with sintilimab and a bevacizumab biosimilar presented promising results [22].”
ResultHepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 14
“…antibody, demonstrated both better overall survival (HR, 0.57; p < 0.0001) and progression-free survival (HR, 0.56; p < 0.0001) benefits [73] as well as improvement in ORR, time-to-recurrence, duration of response, and depth of response compared with sorafenib in the updated data [74].”
InfluentialImmunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12
Mu, M.-Y., Chen, Z.-X., Cao, Y.-Z., Fu, X., Qiu, L.-J., Qi, H., & Gao, F. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217851 · Cited by 14
Self-citationZhang, L., Sun, J., Wang, K., Zhao, H., Zhang, X., & Ren, Z. (2022) · Current Oncology · doi:10.3390/curroncol29100575 · Cited by 13
“[43] 2019–2020 Randomized 50 571 0:15:85:0 0:14:86:0 53 (21–82) f 54 (28–77) f 334 (88) 171 (90) 1 L Sintilmab + IBI305 Sorafenib”
BackgroundResultInfluentialSelf-citationRizzo, A., Ricci, A. D., Fanizzi, A., Massafra, R., Luca, R. D., & Brandi, G. (2023) · Current Oncology · doi:10.3390/curroncol30010057 · Cited by 13
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
Gordan, J. D., Keenan, B. P., Lim, H. C., Yarchoan, M. M., & Kelley, R. K. (2023) · Drugs · doi:10.1007/s40265-023-01907-3 · Cited by 12
“0001), which was consistent with the IMbrave150 trial results and provided further support for the efficacy of anti-PD-1/anti-VEGF combinations in this setting [39].”
ResultLin, L.-W., Yan, L., Ke, K., Yang, W. B., Lin, J., & Huang, N. (2023) · Brachytherapy · doi:10.1016/j.brachy.2023.06.229 · Cited by 12
Self-citationLiu, C., Zhu, S., Dong, Y., Shao, J., Liu, B., & Shen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930096 · Cited by 12
“A large number of research data in the past 5 Frontiers in Immunology | www.frontiersin.org 2 years have shown that anti-angiogenic drugs in combination with PD-1 antibody therapy can further improve patient’s survival, such as Imbrave150 (3), Rescue (13), Orient-32 (14), Keynote-524 (6) and so on.”
BackgroundSelf-citationImmunotherapy and Hepatocellular Cancer: Where Are We Now?
Valéry, M., Cervantes, B., Samaha, R., Gelli, M., Smolenschi, C., Fuerea, A. C., Tselikas, L., Prieux‐Klotz, C., Hollebecque, A., Boige, V., et al. (2022) · Cancers · doi:10.3390/cancers14184523 · Cited by 13
“Finally, the combination of sintilimab (a PD-1 inhibitor) and a biosimilar of bevacizumab (IBI305) is under evaluation versus sorafenib in advanced HCC in the phase II/III ORIENT-32 trial.”
Immunotherapy for hepatobiliary malignancies: Progress and prospective
Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.09.002 · Cited by 12
Zhang, Y., Wang, M., Chen, Q., Deng, Y., Chen, J., Dai, Y., Luo, S., Xu, J., Zhao, H. Y., & Cai, J. (2022) · Liver Cancer · doi:10.1159/000528698 · Cited by 12
“Four treatment groups from 3 studies evaluated AEs with CTCAE version 5.0 [37, 40, 41].”
MethodInfluentialSelf-citationZeng, X., Jia, Y., Chen, H., Luo, Q., Zhao, H., Liang, G., Chen, W., & Li, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04775-2 · Cited by 11
Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151967 · Cited by 11
Fu, Z., Zhang, X., Gao, Y., Fan, J., & Gao, Q. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1320 · Cited by 11
Self-citationChen, Y., Yang, C., Sheng, L., Jiang, H., & Song, B. (2023) · Cancers · doi:10.3390/cancers15194677 · Cited by 11
Self-citationImmune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications
Zhang, W., Liu, M., Li, W., & Song, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002919 · Cited by 11
“[84,85] Previous studies reported that nivolumab (a fully human IgG4 mAb against PD-1) has substantial therapeutic activity in patients with R/R HL. [86,87] Other studies have reported limited efficacy of nivolumab monotherapy in R/R FL or DLBCL. [88,89] Primary mediastinal B-cell lymphoma (PMBL)…”
BackgroundFinn, R. S., Kudo, M., Barnes, G., Meyer, T., Boisserie, F., Abdrashitov, R., Chen, Y., Li, S., Zhu, A. X., Qin, S., et al. (2024) · Liver Cancer · doi:10.1159/000537966 · Cited by 12
Self-citationMa, J., Zhang, H., Zheng, R., Wang, S., & Ding, L. (2024) · The Oncologist · doi:10.1093/oncolo/oyae209 · Cited by 14
Yuan, G., Chen, Y., Zhu, P., Deng, Q., Su, K., Liu, J., Wang, Y., Li, R., Li, W., Zang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37616 · Cited by 12
“Key inclusion criteria [1]: age between 18 and 75 years [2]; no prior systemic therapy [3]; Barcelona Clinical Liver Cancer (BCLC) stages B/C [4]; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 – 2 [5]; Child-Pugh class A/B [6]; at least one evaluable lesion [7]; not received…”
BackgroundSelf-citationLin, Y., Yue, W. R., Shi, H., Li, J., & Qun, Y. Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546886 · Cited by 12
PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers
Xu, P., Hong, C., Liu, L., & Xiao, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189334 · Cited by 12
Chen, Q., Chen, S., & Zhao, M. D. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s514881 · Cited by 15
“Other ICI-based clinical trials, such as HIMALAYA 9 and ORIENT-32, 10 also yielded promising results, solidifying the role of immunotherapy in the evolving narrative of HCC treatment.”
Application of Immune Checkpoint Inhibitors in Cancer
Chen, Z., Song, Z., Den, S., Zhang, W., Han, M., Lan, T., Du, X., Ning, J., Chen, X., Lin, H., et al. (2025) · MedComm · doi:10.1002/mco2.70176 · Cited by 13
Self-citation
Metadata
- Authors
- Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., Chen, Z., Liu, B., Jia, W., Wu, J., Wang, J., Shao, G., Zhang, B., Shan, Y., Meng, Z., Wu, J., Gu, S., Yang, W., Liu, C., Shi, X., Gao, Z., Yin, T., Cui, J., Huang, M., Xing, B., Mao, Y., Teng, G., Qin, Y., Wang, J., Xia, F., Yin, G., Yang, Y., Chen, M., Wang, Y., Zhou, H., & Fan, J.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Chinese PLA General Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Nantong University (CN)
- Henan Provincial People's Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Sichuan University (CN)
- Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Anhui Provincial Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Zhejiang Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Fudan University (CN)
- Hunan Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Shandong Tumor Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Hubei Cancer Hospital (CN)
- First Hospital of Jilin University (CN)
- Peking Union Medical College Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Southwest Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Innovent Biologics (China) (CN)
- Corresponding author
- Fan, Jia
- ORCID
- Ren, Zhenggang
- Xu, Jianming
- Bai, Yuxian
- Xu, Aibing
- Cang, Shundong
- Du, Chengyou
- Li, Qiu
- Lu, Yinying
- Chen, Yajin
- Guo, Yabing
- Chen, Zhendong
- Liu, Baorui
- Jia, Weidong
- Wu, Jian
- Wang, Junye
- Shao, Guoliang
- Zhang, Bixiang
- Shan, Yunfeng
- Meng, Zhiqiang
- Wu, Jianbing
- Gu, Shanzhi
- Yang, Wei
- Liu, Chao
- Gao, Zhenyuan
- Yin, Tao
- Cui, Jiuwei
- Huang, Ming
- Mao, Yilei
- Qin, Yanru
- Wang, Jinhai
- Yin, Guowen
- Yang, Yong
- Chen, Mingxia
- Zhou, Hui
- Fan, Jia
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 22
- Issue
- 7
- Pages
- 977-990
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3166753505
- Cited by
- 1,124
- References
- 30
- Citations by year
- 2026: 162 · 2025: 241 · 2024: 273 · 2023: 247 · 2022: 178 · 2021: 21
- FWCI
- 100.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-08-01)
- Open access
- closed
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sintilimab, bevacizumab biosimilar, sorafenib, hepatocellular carcinoma, PD-1 inhibitors, first-line therapy, unresectable liver cancer, hepatitis B virus, overall survival, progression-free survival, combination immunotherapy, anti-angiogenic therapy, China, safety and tolerability, macrovascular invasion
- MeSH terms
- Bevacizumab, Sorafenib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, China, Female, Hepatitis B, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Time Factors, Disease Progression, Young Adult, Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
